Seres Therapeutics, Inc. (MCRB) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 5, 2026, Seres Therapeutics, Inc. (MCRB) trades at a price-to-earnings ratio of -0.5x, with a stock price of $9.13 and trailing twelve-month earnings per share of $0.61.
The current P/E is 102% below its 5-year average of 31.7x. Over the past five years, MCRB's P/E has ranged from a low of 31.7x to a high of 31.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.2x, MCRB trades at a 102% discount to its sector peers. The sector includes 226 companies with P/E ratios ranging from 0.0x to 194.6x.
Relative to the broader market, MCRB trades at a notable discount to the S&P 500 median P/E of 26.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MCRB DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $19.24 | $0.61 | 31.7x | +0% |
Average P/E for displayed period: 31.7x
See MCRB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MCRB Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare MCRB vs LLY
See how MCRB stacks up against sector leader Eli Lilly and Company.
Start ComparisonFrequently Asked Questions
Is MCRB stock overvalued or undervalued?
MCRB trades at -0.5x P/E, below its 5-year average of 31.7x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does MCRB's valuation compare to peers?
Seres Therapeutics, Inc. P/E of -0.5x compares to sector median of 23.2x. The discount suggests lower growth expectations or higher risk.
What is MCRB's PEG ratio?
MCRB PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.